Caris Life Sciences (CAI) Non-Current Assets (2024 - 2026)

Caris Life Sciences' Non-Current Assets history runs 3 years deep, the most recent figure standing at $148.2 million for Q1 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $148.2 million in Q1 2026; TTM through Mar 2026 was $528.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $127.9 million, changed 0.11% from the prior year.
• Non-Current Assets advanced to $148.2 million in Q1 2026 per CAI's latest filing, from $127.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $148.2 million in Q1 2026 and bottomed at $121.7 million in Q2 2025.
• The 3-year median for Non-Current Assets is $128.0 million (2024), against an average of $131.2 million.
• Biggest YoY gain for Non-Current Assets was 0.11% in 2025; the steepest drop was 0.11% in 2025.
• Year by year, Non-Current Assets stood at $128.0 million in 2024, then retreated by 0.11% to $127.9 million in 2025, then grew by 15.91% to $148.2 million in 2026.
• Per Business Quant, the three latest CAI Non-Current Assets figures stand at $148.2 million (Q1 2026), $127.9 million (Q4 2025), and $130.3 million (Q3 2025).